Global Leading Market Research Publisher QYResearch announces the release of its latest report “Pharmaceutical and Nutraceutical Empty Capsules – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pharmaceutical and Nutraceutical Empty Capsules market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical and nutraceutical manufacturers, oral dosage forms require a delivery vehicle that protects active ingredients from environmental degradation (light, oxygen, moisture, gastric acid) while enabling controlled release at target sites. Traditional tablets require complex formulation and compression; liquid fills are unsuitable for many APIs. The pharmaceutical and nutraceutical empty capsule addresses this through versatile oral delivery: hollow capsules made from gelatin, HPMC, or algal polysaccharides, available in immediate-release, sustained-release, or enteric-coated forms to achieve specific release profiles. According to QYResearch’s updated model, the global market for Pharmaceutical and Nutraceutical Empty Capsules was estimated to be worth US$ 2,935 million in 2025 and is projected to reach US$ 4,417 million, growing at a CAGR of 6.1% from 2026 to 2032. Pharmaceutical and nutraceutical empty capsules are hollow capsule dosage forms specifically designed to encapsulate pharmaceuticals or dietary supplements. They can be made from gelatin, hydroxypropyl methylcellulose (HPMC), or other edible plant-based polysaccharides. These capsules offer excellent biocompatibility, chemical stability, and controlled dissolution properties, protecting active ingredients from light, oxygen, moisture, and gastric acid to ensure the stability and efficacy of the drug or nutritional component. Pharmaceutical capsules are mainly used for oral prescription and over-the-counter drugs, while nutraceutical capsules deliver vitamins, minerals, probiotics, and functional food ingredients. Depending on formulation requirements, they can be designed as immediate-release, sustained-release, or enteric-coated forms to achieve specific release sites and timing. In 2024, the global sales volume of Pharmaceutical and Nutraceutical Empty Capsules reached 1,210 billion capsules, with an average price of 23.5 USD per 10,000 capsules.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098139/pharmaceutical-and-nutraceutical-empty-capsules
1. Technical Architecture: Capsule Sizes and Release Profiles
Pharmaceutical and nutraceutical empty capsules are segmented by size (capacity) and release profile:
| Capsule Size | Fill Volume (mL) | Typical Applications | Price per 10,000 capsules (USD) | Market Share (Units) |
|---|---|---|---|---|
| 00# | 0.91-0.95 | High-dose APIs, probiotics (50B+ CFU) | $25-35 | 15% |
| 0# | 0.68-0.72 | Standard prescription drugs, nutraceuticals | $22-30 | 25% |
| 1# | 0.48-0.52 | Probiotics, enzymes, herbal extracts | $20-28 | 30% |
| 2# | 0.36-0.40 | Small-dose drugs, pediatric formulations | $18-26 | 15% |
| 3# | 0.27-0.30 | Low-dose APIs, specialty | $16-24 | 10% |
| Others | 0.20-1.00 | Custom, veterinary | $15-35 | 5% |
Release profile types:
| Release Profile | Mechanism | Typical Applications | Price Premium |
|---|---|---|---|
| Immediate-release | Capsule dissolves rapidly (5-15 min) | Most pharmaceuticals, vitamins | Baseline |
| Sustained-release | Extended-release matrix or coated beads | Once-daily formulations, chronic conditions | +20-40% |
| Enteric-coated | Acid-resistant coating (gastric protection) | Acid-sensitive APIs, probiotics, NSAIDs | +30-50% |
| Delayed-release | Time or pH-dependent release | Colon-targeted (IBD), pulsatile | +40-60% |
Key technical challenge – capsule material compatibility with fill formulations: Over the past six months, several advancements have emerged:
- Lonza (February 2026) introduced a “universal” HPMC capsule compatible with aldehydes (e.g., glutaraldehyde in some fills), eliminating cross-linking issues (gelatin cross-links with aldehydes, delaying dissolution).
- ACG Associated Capsules (March 2026) commercialized a “low-moisture” gelatin capsule (<10% moisture) for moisture-sensitive APIs (probiotics, enzymes), extending shelf life by 12 months.
- Qualicaps (January 2026) launched a pullulan-based capsule with oxygen barrier 3x gelatin, protecting oxygen-sensitive probiotics (Lactobacillus, Bifidobacterium) for 24 months.
Industry insight – capsule material comparison:
| Parameter | Gelatin | HPMC | Algal (Carrageenan) | Pullulan |
|---|---|---|---|---|
| Source | Animal (bovine/porcine) | Plant (wood pulp) | Marine algae | Plant (tapioca) |
| Vegetarian | No | Yes | Yes | Yes |
| Moisture content | 13-16% | 3-7% | 5-9% | 5-8% |
| Cross-linking risk | Yes (with aldehydes) | No | No | No |
| Oxygen barrier | Poor | Moderate | Good | Very good |
| Acid resistance | None | None (requires coating) | Natural (alginate) | None |
| Cost per 1,000 | $2.00-3.20 | $2.80-4.20 | $3.20-4.60 | $3.50-5.00 |
2. Market Segmentation: Capsule Size and Application
The Pharmaceutical and Nutraceutical Empty Capsules market is segmented as below:
Key Players: Qualicaps (US/Spain), Lonza (Switzerland/US), ACG Associated Capsules (India), Suheung (South Korea), CapsCanada (Canada), Sunil Healthcare (India), Evonik Specialty Chemicals (Germany), Shandong Healsee Capsule (China), Anhui Huangshan Capsule (China), Farmacapsulas (Colombia), Guangzhou Jiuzhou Capsule (China), Hunan Er-Kang Pharmaceutical (China), Hebei Kangxin Plant Capsule (China), Zhejiang Yueshan Capsule (China), Zhejiang Tianlong Capsule (China), Zhejiang Xinchang Kangping Capsule (China), Jiangsu Kangyoujian Biotechnology (China), Guizhou Guang De Li Pharmaceuticals (China), SUZHOU CAPSUGEL (China), Chongqing Heng Sheng Pharmaceutical (China), Jiangsu Youli Capsule (China), Jinan Gaohua Medicinal Capsule (China), Qingdao Gather Great Ocean Algae Industry Group (China), GoCaps GmbH (Germany)
Segment by Capsule Size:
- 1# – Largest segment (30% of 2025 units). Most common for nutraceuticals.
- 0# – 25% of units. Standard pharmaceuticals.
- 00# – 15% of units. High-dose products.
- 2# – 15% of units. Small-dose products.
- 3# – 10% of units. Low-dose specialty.
- Others – 5% of units.
Segment by Application:
- Pharmaceuticals – Largest segment (55% of revenue). Prescription drugs, OTC medications, clinical trial supplies.
- Health Supplements (Nutraceuticals) – 40% of revenue (fastest-growing, 8% CAGR). Vitamins, minerals, probiotics, enzymes, herbal extracts.
- Others – Functional foods, veterinary (5% of revenue).
Typical user case – sustained-release once-daily formulation: A pharmaceutical company reformulates a thrice-daily immediate-release drug to once-daily sustained-release capsule. Sustained-release beads (coated with polymer) filled into 0# HPMC capsule. Results: improved patient compliance (once vs. three times daily), reduced peak-trough fluctuations (fewer side effects), and patent extension (new formulation). Capsule cost premium: $0.005 per capsule ($1.8M annually for 1B capsules). Value: extended market exclusivity (+$100M+ revenue).
Exclusive observation – “capsule-in-capsule” technology: Lonza’s “Capsule-in-Capsule” (Capsugel) features a smaller capsule inside a larger capsule, enabling combination products (two APIs) or sequential release (outer capsule releases first, inner capsule releases later). Used for fixed-dose combinations (e.g., NSAID + PPI) and chronotherapy (nighttime dosing). Growing at 10% CAGR.
3. Regional Dynamics and Healthcare Demand
| Region | Market Share (2025) | Key Drivers |
|---|---|---|
| Asia-Pacific | 45% | Largest manufacturing base (China, India, South Korea), domestic manufacturers (Healsee, Huangshan, Jiuzhou, Er-Kang, Kangxin, Yueshan, Tianlong, Kangping, Kangyoujian, Guang De Li, Suzhou Capsugel, Heng Sheng, Youli, Gaohua, Qingdao Gather), cost leadership |
| North America | 25% | Large pharmaceutical and nutraceutical market, vegetarian demand, Lonza/Qualicaps leadership |
| Europe | 20% | Strong pharmaceutical industry, ACG/Suheung/CapsCanada/Evonik/GoCaps leadership |
| RoW | 10% | Emerging markets (Latin America – Farmacapsulas, Middle East) |
Exclusive observation – “empty capsule” market consolidation: Top 5 players (Lonza, Qualicaps, ACG, Suheung, CapsCanada) account for 60% of global revenue. Chinese manufacturers (20+ companies) account for 30% of global volume but lower value (commodity gelatin capsules). Consolidation driven by economies of scale (capsule manufacturing is capital-intensive, high-volume).
4. Competitive Landscape and Outlook
| Tier | Supplier | Key Strengths | Focus |
|---|---|---|---|
| 1 | Global leaders | Lonza, Qualicaps, ACG, Suheung, CapsCanada, Evonik | Full size range, multiple materials (gelatin, HPMC, pullulan, algal), enteric-coated, sustained-release, global distribution, premium pricing (+20-30%) |
| 2 | Chinese domestic leaders | Shandong Healsee, Anhui Huangshan, Guangzhou Jiuzhou, Hunan Er-Kang, Hebei Kangxin, Zhejiang Yueshan, Zhejiang Tianlong, Zhejiang Kangping, Jiangsu Kangyoujian, Guizhou Guang De Li, Suzhou Capsugel, Chongqing Heng Sheng, Jiangsu Youli, Jinan Gaohua, Qingdao Gather | Cost leadership (30-50% below global), domestic market dominance, export |
| 2 | Regional specialists | Farmacapsulas (Colombia), Sunil Healthcare (India), GoCaps (Germany) | Regional markets, niche (algal, pullulan) |
Technology roadmap (2027-2030):
- 3D-printed personalized capsules – Custom-size capsules for pediatric or geriatric patients (dose titration). Pilot stage.
- Smart capsules with embedded sensors – Ingestible capsules with pH, temperature, or pressure sensors for diagnostic applications (e.g., GI motility assessment). Research stage.
- Biodegradable capsules from agricultural waste – Plant-based capsules from rice straw, wheat bran, or corn stover (circular economy). Pilot stage.
With 6.1% CAGR and 1.21 trillion capsules sold in 2024, the pharmaceutical and nutraceutical empty capsule market benefits from oral drug delivery dominance, nutraceutical growth, and vegetarian/vegan demand. Key growth drivers: aging population (chronic disease management), self-care trends (OTC and supplements), and formulation innovation (sustained-release, enteric-coated). Risks include competition from tablets (lower cost for high-volume), gelatin supply chain volatility (bovine/porcine diseases), and regulatory changes (capsule dissolution standards).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
